Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic
Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.
You may also be interested in...
Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata
Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.